Ovid Therapeutics (OVID) Set to Release Quarterly Earnings on Wednesday

Ovid Therapeutics (NASDAQ:OVID) is expected to post its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect Ovid Therapeutics to announce earnings of ($0.08) per share and revenue of $0.03 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Ovid Therapeutics (NASDAQ:OVID) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.04. The company had revenue of $0.73 million for the quarter, compared to the consensus estimate of $0.02 million. On average, analysts expect Ovid Therapeutics to post ($0.37) EPS for the current fiscal year and ($0.38) EPS for the next fiscal year.

Ovid Therapeutics Trading Up 0.8%

OVID opened at $2.41 on Wednesday. The firm’s 50-day simple moving average is $2.52 and its 200-day simple moving average is $2.36. The company has a quick ratio of 12.39, a current ratio of 12.39 and a debt-to-equity ratio of 0.05. Ovid Therapeutics has a twelve month low of $1.18 and a twelve month high of $3.11.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. HC Wainwright upped their price objective on shares of Ovid Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a research note on Friday, September 11th. Roth Capital reiterated a “buy” rating and issued a $8.00 price objective on shares of Ovid Therapeutics in a research report on Thursday, September 3rd. Oppenheimer upped their target price on shares of Ovid Therapeutics from $7.00 to $9.00 and gave the stock an “outperform” rating in a research report on Monday, August 3rd. Wolfe Research assumed coverage on Ovid Therapeutics in a report on Thursday, October 15th. They issued an “outperform” rating and a $5.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ovid Therapeutics in a report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Ovid Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.00.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines for epilepsies and other disorders of the central nervous system. The company’s research has concentrated on conditions with significant unmet medical needs, including rare epileptic and neurodevelopmental disorders.

Ovid’s pipeline has included soticlestat, an investigational therapy developed in collaboration with Takeda Pharmaceutical Company for developmental and epileptic encephalopathies such as Dravet syndrome and Lennox-Gastaut syndrome.